Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is included among the Top 10 Reddit Stocks That Will Skyrocket.

On April 10, Morgan Stanley raised its price recommendation on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $612 from $596. It maintained an Overweight rating on the shares. The firm said it updated its models across its biopharma coverage, reflecting IQVIA trends and intra-quarter developments ahead of Q1 earnings for the group.

On April 7, RBC Capital Markets analyst Brian Abrahams raised the firm’s price target on VRTX to $543 from $541 and maintained an Outperform rating. The update came as part of a broader research note previewing Q1 results in biotech. The analyst said seasonal pressures tied to gross-to-net adjustments, reimbursement resets, and fewer selling days tend to weigh on Q1. These effects may be more noticeable this time due to weather disruptions, especially for newly launched and in-clinic products. At the same time, he noted that a pickup in M&A activity, along with clearer expectations around tariffs and Most Favored Nation drug pricing, could help balance those pressures and support overall sentiment in the sector.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) operates as a global biotechnology company focused on developing medicines for serious diseases. It invests in scientific innovation and targets specialty markets. The company has seven approved medicines, including five that treat the underlying cause of cystic fibrosis, one for severe sickle cell disease and transfusion-dependent beta thalassemia, and one for moderate-to-severe acute pain.

READ NEXT: 10 Healthcare Stocks with Highest Dividends and 10 Fastest Growing Dividend Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.